Chief Executive Officer Soinski Jeffrey M sold $2,054 worth of shares (3,690 units at $0.56), decreasing direct ownership by 6% to 55,265 units (SEC Form 4)

$AVGR
Medical/Dental Instruments
Health Care
Get the next $AVGR alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SOINSKI JEFFREY M

(Last) (First) (Middle)
400 CHESAPEAKE DRIVE

(Street)
REDWOOD CITY CA 94063

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Avinger Inc [ AVGR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
01/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/23/2025 S 3,690(1) D $0.5567 55,265 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs on January 18, 2025. This sell to cover transaction does not represent a discretionary trade by the reporting person.
/s/ Jeffrey M. Soinski 01/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $AVGR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AVGR

DatePrice TargetRatingAnalyst
11/15/2021$2.50 → $2.00Buy
Aegis Capital
6/29/2021$2.50Buy
B. Riley Securities
More analyst ratings

$AVGR
Press Releases

Fastest customizable press release news feed in the world

See more
  • Avinger Reports Third Quarter 2024 Results

    Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the third quarter ended September 30, 2024.Third Quarter and Recent HighlightsReported third quarter 2024 revenue of $1.7 million, sequentially increased gross margin to 26%.Implemented cost reduction program designed to streamline operating costs of the peripheral business and increase focus on coronary product development

    $AVGR
    Medical/Dental Instruments
    Health Care
  • Avinger to Announce Third Quarter 2024 Results on November 7, 2024

    REDWOOD CITY, CA / ACCESSWIRE / October 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the third quarter 2024 after the close of trading on Thursday, November 7, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.To join the call by telephone, please dial +1- 973-528-0011 and use passcode 442577. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.avinger.co

    $AVGR
    Medical/Dental Instruments
    Health Care
  • Avinger Releases Updated Data From IMAGE-BTK in Webinar Featuring Key Opinion Leaders in the Field of Vascular Intervention

    REDWOOD CITY, CA / ACCESSWIRE / October 24, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease hosted a physician-focused webinar entitled, "New Approaches to Treating Peripheral Artery Disease (PAD) Below-the-Knee (BTK) and Promising New BTK Data." A recording of the webinar may be accessed at https://pages.avinger.com/webinar-new-approaches-to-treating-btk-pad.The webinar featured key opinion leaders in the field of vascular intervention from different specialties and geographies as follows:Dr. Michael Lichtenberg, an angiologist and the

    $AVGR
    Medical/Dental Instruments
    Health Care

$AVGR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$AVGR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$AVGR
Leadership Updates

Live Leadership Updates

See more
  • Avinger Appoints Thomas P. Davis, MD, FACC as Chief Medical Officer

    REDWOOD CITY, CA / ACCESSWIRE / August 5, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced the appointment of Thomas P. Davis, MD, FACC, as Chief Medical Officer for its peripheral business. As a highly experienced interventional cardiologist and key opinion leader (KOL) in the peripheral vascular space, Dr. Davis has operated at the forefront of medical device innovation and advancing patient care in a career spanning more than three decades. Dr. Davis has pioneered the use of several cutting-edge interventional technolo

    $AVGR
    Medical/Dental Instruments
    Health Care
  • BrightInsight Adds Medical Device and Biopharmaceutical Experts, Tamara Elias, M.D., and Scott Huennekens to Advisory Council

    SAN JOSE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennekens, executive chairperson at Hyperfine, Wondr Medical, Acutus Medical and Envista Holdings Corporation, to the BrightInsight Advisory Council. Dr. Elias and Huennekens bring deep and complimentary experience to this group of industry experts, who work with BrightInsight leadership to advance the company's vision to transform patient outcomes globally through the power of digital technology. Dr. Elias and Huennek

    $AFIB
    $AVGR
    $HYPR
    $NUVA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments
  • Avinger Announces Annual Meeting Results

    REDWOOD CITY, CA / ACCESSWIRE / December 23, 2020 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced results of its annual meeting of stockholders (the "Annual Meeting"), concluded on December 23, 2020. At the Annual Meeting, proposals were presented to elect one director to serve until the 2023 annual meeting, to ratify the appointment of the Company's public accountant for the year ended December 31, 2020, to approve an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock spl

    $AVGR
    Medical/Dental Instruments
    Health Care

$AVGR
Financials

Live finance-specific insights

See more
  • Avinger Reports Third Quarter 2024 Results

    Lower Operating Cost Profile Drives Improved Productivity, Increased Gross Margin REDWOOD CITY, CA / ACCESSWIRE / November 7, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the third quarter ended September 30, 2024.Third Quarter and Recent HighlightsReported third quarter 2024 revenue of $1.7 million, sequentially increased gross margin to 26%.Implemented cost reduction program designed to streamline operating costs of the peripheral business and increase focus on coronary product development

    $AVGR
    Medical/Dental Instruments
    Health Care
  • Avinger to Announce Third Quarter 2024 Results on November 7, 2024

    REDWOOD CITY, CA / ACCESSWIRE / October 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the third quarter 2024 after the close of trading on Thursday, November 7, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.To join the call by telephone, please dial +1- 973-528-0011 and use passcode 442577. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.avinger.co

    $AVGR
    Medical/Dental Instruments
    Health Care
  • Avinger to Announce Second Quarter 2024 Results on August 8, 2024

    REDWOOD CITY, CA / ACCESSWIRE / July 29, 2024 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the second quarter 2024 after the close of trading on Thursday, August 8, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.To join the call by telephone, please dial +1-848-280-6550 and use passcode Avinger. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.avinger.com.A

    $AVGR
    Medical/Dental Instruments
    Health Care

$AVGR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more